Project Details
Description
Project Summary
Interstitial lung diseases (ILDs) including idiopathic and other forms of pulmonary fibrosis represent a major
and growing medical burden. While FDA-approved therapeutics limit progression of fibrotic ILDs, they do not
fundamentally alter the course of these diseases. A central element of fibrosis progression in ILDs is the
persistent activation of fibroblasts to a fibrogenic state; whereas transient fibroblast activation promotes wound
healing, aberrant and prolonged fibroblast activation promotes fibrotic ECM deposition and hinders restoration
of cellular homeostasis in epithelial and hematopoietic compartments. Hence, understanding how fibroblasts
become activated and then locked in fibrogenic states is central to the development more effective therapies
for fibrotic ILDs. Based on extensive preliminary data demonstrating a key role for the transcription factor
Runx1 in fibroblast activation and fibrogenic memory in mouse and human fibrotic lung tissue, we will test the
central hypothesis that fibroblasts gain and maintain a memory of fibrogenic activation that primes them for
amplified activation upon repeated injury, and that Runx1 plays a central role in this activation and fibrogenic
memory. We propose to test this hypothesis in three specific aims. In the first aim we will use a mouse model
to identify the location, abundance and specific transcriptional targets of Runx1 engagement during fibrosis
initiation, resolution and persistence. In the second aim we will test whether conditional deletion of Runx1
attenuates fibrosis and fibroblast memory, diminishes persistent fibrosis in a repeated bleomycin injury model,
and restores homeostatic states in mesenchymal and other lung compartments. In the final aim we will analyze
human lung tissue and fresh sorted fibroblasts to delineate Runx1 engagement, targets and functional effects
relevant to human disease. In both mouse and human tissue, we will seek to identify the role of mechanical
and biochemical signals in conferring fibrogenic memory and Runx1 activation and will test established and
investigational therapeutics for their capacity to erase fibrogenic memory. Together these studies will test the
function and regulation of Runx1 in fibrogenic cell activation and memory in mouse models and human tissue,
potentially identifying a novel targetable mechanism underlying fibrotic ILD progression.
Status | Finished |
---|---|
Effective start/end date | 12/1/22 → 11/30/23 |
Funding
- National Heart, Lung, and Blood Institute: $596,040.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.